NURLF (Neural Therapeutics) Additional Paid-In Capital: $0.07 Mil(As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Additional Paid-In Capital?

Neural Therapeutics NURLF Additional Paid-In Capital is $0.07 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.


Neural Therapeutics's quarterly additional paid-in capital declined from Jul. 2025 ($0.07 Mil) to Oct. 2025 ($0.07 Mil) but then increased from Oct. 2025 ($0.07 Mil) to Jan. 2026 ($0.07 Mil).

Neural Therapeutics's annual additional paid-in capital stayed the same from Jul. 2023 ($0.00 Mil) to Jul. 2024 ($0.00 Mil) but then increased from Jul. 2024 ($0.00 Mil) to Jul. 2025 ($0.07 Mil).

Neural Therapeutics Additional Paid-In Capital Related Terms

Neural Therapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Additional Paid-In Capital Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Additional Paid-In Capital
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.07

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.07 0.07 0.07

Neural Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $0.07 Mil mean?
Neural Therapeutics (NURLF) has a Additional Paid-In Capital of $0.07 Mil as of Jan. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Neural Therapeutics and its competitors.
Is Neural Therapeutics' Additional Paid-In Capital too high?
Neural Therapeutics' current Additional Paid-In Capital is $0.07 Mil.
How does Neural Therapeutics' Additional Paid-In Capital compare to VRTX and REGN?
Neural Therapeutics' Additional Paid-In Capital of $0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current Additional Paid-In Capital is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current Additional Paid-In Capital of $0.07 Mil. The current Additional Paid-In Capital is $0.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current Additional Paid-In Capital is $0.07 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:GermanyNURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.